• menu

    BLOG

    MARKET INTEL by PharmaCompass

    CONTENT by Suppliers

    News

    FAMAR CDMO- From early development to commercial manufacturing.
    (2S,3R,4R,5S,6R)-2-(4-chloro-3-(4-ethoxybenzyl)phenyl)-6- (hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol
    |
    Stock Recap #PipelineProspector

    Pipeline Prospector October 2025: Novartis to buy Avidity for US$ 12 bn; FDA approves Bayer’s med to treat hot flashes

    October was abuzz with dealmaking. Pharma majors such as Novartis, Novo Nordisk, and Bristol Myers
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.